EA5 is named as a drug or biological intervention in 2 clinical trials in our China trial register, 1 of which is recruiting. The lead sponsor is Shanghai Lanyi Therapeutics Co., Ltd.. Registered phase: Phase 1. Conditions studied include PNH - Paroxysmal Nocturnal Hemoglobinuria; Generalized Myasthenia Gravis (gMG).
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07256301 | A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) (ClinicalTrials.gov ↗) PNH - Paroxysmal Nocturnal Hemoglobinuria |
Phase 1 | Recruiting |
| NCT07818291 | An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis (ClinicalTrials.gov ↗) Generalized Myasthenia Gravis (gMG) |
Phase 1 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| PNH - Paroxysmal Nocturnal Hemoglobinuria | 1 |
| Generalized Myasthenia Gravis (gMG) | 1 |
| Lead sponsor | Trials |
|---|---|
| Shanghai Lanyi Therapeutics Co., Ltd. | 2 |
| Register | EA5 trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how EA5 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists EA5 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.